Brief: Compass Pathways Successfully Achieves Primary Endpoint In First Phase 3 Trial
23/06/2025 11:31
June 23 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC - COMP360 SHOWS SIGNIFICANT REDUCTION IN SYMPTOM SEVERITY IN PHASE 3 TRIAL COMPASS PATHWAYS PLC - DSMB FINDS NO UNEXPECTED SAFETY ISSUES WITH COMP360 COMPASS PATHWAYS PLC - COMP006 TRIAL 26-WEEK DATA EXPECTED IN SECOND HALF OF 2026 Source text: ID:nBw48NGxNa Further company coverage: CMPS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications